Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...

AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 ...

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

This innovative approach works by NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

Tiziana Life Sciences (TLSA) announced the publication of a landmark study in Nature Neuroscience demonstrating that nasal administration of ...

Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.

Tiziana Life Sciences, Ltd. has entered into a product development services agreement with Renaissance Lakewood LLC to enhance and scale up the formulation of its lead candidate, intranasal ...

In this article, we are going to take a look at where Tiziana Life Sciences Ltd (NASDAQ:TLSA) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...